BTK and cancer: MRS is emerging as particularly effective in detecting and monitoring biomarkers of response to kinase inhibition, as shown using MCL as cancer model and the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, as index kinase inhibitor [6–8].